Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects

By Graefe-Mody E. U.   Padula S.   Ring A.   Withopf B.   Dugi K. A.  

Current Medical Research and Opinion, Vol. 25, Iss. 8, 2009-08 ,pp. : 1963-1972

Informa Healthcare

Access to resources Recommend Favorite

Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers

By Huang H.-L. A.   Vaidyanathan S.   Yeh C.-M.   Bizot M.-N.   Dieterich H. A.   Dole W. P.   Howard D.  

Current Medical Research and Opinion, Vol. 24, Iss. 9, 2008-09 ,pp. : 2449-2456

Informa Healthcare

Access to resources Recommend Favorite

Direct renin inhibition: an evaluation of the safety and tolerability of aliskiren

By Rashid Haroonur  

Current Medical Research and Opinion, Vol. 24, Iss. 9, 2008-09 ,pp. : 2627-2637

Informa Healthcare

Access to resources Recommend Favorite

Aliskiren, the first approved renin inhibitor: Clinical application and safety in the treatment of hypertension

By Riccioni Graziano  

Advances in Therapy, Vol. 26, Iss. 7, 2009-07 ,pp. : 700-710

Springer Publishing Company

Access to resources Recommend Favorite

Plasma Thrombin-Activatable Fibrinolytic Inhibitor (TAFI) among Healthy Subjects and Patients with Vascular Diseases: A Validation Study

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 33, Iss. 5-6, 2005-01 ,pp. : 382-386

Karger

Access to resources Recommend Favorite